



GALLEON PHARMACEUTICALS, LLC

Galleon is a specialty pharmaceutical company initially focusing on infectious disease therapeutics. To address an emerging crisis in antibiotic-resistant infections, Galleon is “re-inventing” existing medicines by applying breakthroughs in nanoparticle and polymer technology to transform well-established antibiotics from injectable to oral form. Its CIMBUS platform for the first time enables oral administration of aminoglycoside antibiotics that are highly effective against Gram-negative infections. The availability of oral aminoglycosides should allow doctors to avoid hospitalization for many patients with otherwise difficult-to-treat infections.

Rising bacterial resistance rates are making oral antibiotic stand-bys increasingly ineffective, particularly for “Gram-negative” infections of the lungs, urinary tract and skin, which are responsible for a growing proportion of the 20 million people hospitalized for serious infections each year. Some injectable antibiotics are highly effective in treating Gram-negative infections, but they are costly to administer, involving expensive outpatient administration or hospitalization. Galleon is acquiring rights to novel, biodegradable nanoparticle/polymer technology, the CIMBUS platform, which will enable the oral absorption of this class of antibiotics, initially focusing on the well-established and powerful aminoglycoside, amikacin. Preclinical studies of this new formulation using a prototype antibiotic have confirmed the feasibility of the Galleon approach.

Galleon will use its BioAdvance Greenhouse funding to create formulations of aminoglycoside antibiotics that are suitable for once- or twice-daily oral dosing for a variety of Gram-negative infections. By using existing approved medicines as a starting point, Galleon plans to reduce the time, risk and capital required to complete the clinical development and regulatory approval of its products. The company is seeking collaborations and partnerships to extend the applications of its technology and to support the development and commercialization of its products.

Management

James C. Mannion, Ph.D., Chief Executive Officer, has more than 20 years experience in the pharmaceutical, contract research and biotechnology industries, with expertise in efficient drug development, operational management, corporate strategy and fund-raising. Previously president and COO at EpiGenesis, during his tenures at SmithKline Beecham and Quintiles Dr. Mannion directly contributed to major product development and marketing successes for products including Augmentin®, Paxil® and Bactroban®. He holds a B.S. in Pharmacy from Ohio Northern University and a Ph.D. from Purdue University where he was named a Distinguished Alumnus.

Anton Leighton, M.D., Vice President Clinical Development, an international clinical development expert and emergency physician, was a key contributor to the Rocephin® program. He directed clinical programs at Hoffmann-La Roche, Peninsula Pharmaceuticals and CC/ILD Consultants. Dr. Leighton has authored more than 20 publications and abstracts and holds an ECPM Diploma from the University of Basel and an M.D. degree from Johannes Gutenberg University in Germany.

Leisa J. Dennehy, Vice-President Corporate Development, has more than 22 years of strategic marketing and corporate development experience at GlaxoSmithKline, P&G and biotechnology firms. She contributed to Advair® and Ceftin® and recently launched two products Ms. Dennehy holds a B.S. degree from Miami (Ohio) University and an MBA from Duke’s Fuqua School of Business.

For more information contact Dr. Jim Mannion, CEO, Galleon Pharmaceuticals at jimmannion@msn.com.